Navigation Links
China Medicine Announces Record Fourth Quarter and 2008 Results

GUANGZHOU, China, March 26 /PRNewswire-Asia / -- China Medicine Corporation (OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a developer and a leading distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and dietary-supplements, medical devices, and medical formulations in the People's Republic of China ("PRC"), today reported outstanding financial results for the fourth quarter and full year ended December 31, 2008.

    Fourth Quarter 2008 Highlights

    -- Revenues increased 51.2% to $24.4 million
    -- Gross profit increased 30.4% to $5.8 million
    -- Operating income increased 24.5% to $4.2 million
    -- Net income increased 26.6% to $3.5 million
    -- Received approval from the Guangdong Food & Drug Administration
       ("Guangdong FDA") to distribute dental equipment and instruments in
       Guangdong Province
    -- Once again awarded GSP (Good Supply Practice for Pharmaceutical
       Products) certification from State Food and Drug Administration
    -- Received rADTZ patent approval for Australia, South Africa and Korea

    Full Year 2008 Highlights

    -- Total revenues increased 27.4% to $53.6 million
    -- Gross profit increased 25.6% to $15.6 million
    -- Operating income increased 30.0% to $11.0 million
    -- Net income increased 32.7% to $9.1 million, or $0.60 per diluted

''We are very pleased with our fourth quarter and full year 2008 results despite the challenging economic environment. In the fourth quarter, revenue increased 51.2% compared to the same period last year. Any slowdown from the global economic crisis was mitigated by expansion of our distribution network and positive seasonal factors in which orders were booked just prior to the end of the year,'' said Mr. Senshan Yang, CEO and Chairman of China Medicine Corporation.

''Our top selling drugs for the fourth quarter included Hongjin Xiaojie Capsule, which is used for the treatment of coughs, accounted for 5.66% of revenue; Xueshuantong injection, which is used to improve blood circulation, remove vascular stasis and dilate blood vessels, accounted for about 5.44% of revenues; Cinepazide maleate injection, which is used in the treatment of vascular sclerosis, accounted for 4.11% of revenue. During the quarter, we also received approval from the Guangdong Food and Drug Administration (FDA) to distribute dental and oral surgery equipment, which we view as an attractive market in China as the demand for dental services is expected to grow.

Our gross profit margin fell 4% compared to the fourth quarter of 2007 due to intense competition in the Chinese pharmaceutical industry. We are currently taking steps to improve our gross margin, such as upping our efforts to obtain more exclusive distribution rights on high-margin prescription products. We also plan on developing more specialty pharmaceutical products and increasing our existing product offerings. This will help us strengthen our competitive advantages and diversify business risk,'' said Mr. Yang.

Fourth Quarter Results

China Medicine's total revenues in the fourth quarter of 2008 were $24.4 million, an increase of 51.2% over the fourth quarter of 2007. This was attributable to a 66.2% increase in product sales, primarily driven by an increase in over-the-counter product sales made through the company's increased market share in the municipal and rural areas of Guangdong Province. In addition, an earlier Chinese New Year resulted in many orders being booked prior to December 31, 2008, helping to contribute to the Company's strong top line growth.

Product sales in the fourth quarter of 2008 totaled $24.4 million and accounted for 99.97% of total net revenues. Sales of prescription products accounted for 78.94% of total net revenues, and over-the-counter medicines accounted for 17.9% of total revenues during the quarter. Sales of dietary supplements, medical equipment and others accounted for 1.12%, 1.87% and 0.14% respectively. Medical formula sales accounted for 0.03% of total revenues, totaling $7,254, down 99.5% from the fourth quarter of 2007. The decline was due to stricter regulations by the State Food and Drug Administration (SFDA) in China, where approvals for new medical formulas were limited since the process has become more complex due to concerns over food and pharmaceutical safety.

Gross profit in the fourth quarter of 2008 was $5.8 million, an increase of 30.4% over the fourth quarter of 2007. Gross margin was 24% of total revenues, down from 28% of total revenues in the fourth quarter of 2007. The decline in gross margin was due to lower selling prices for some of the pharmaceutical products the Company distributes as the Chinese government set a price ceiling on certain generic drugs. To counter this situation, China Medicine is adjusting its portfolio to increase pharmaceutical products with exclusive distribution rights, which have a higher margin.

Operating expenses in the fourth quarter of 2008 were $1.6 million, up 48.1% from $1.1 million in the fourth quarter of 2007. This increase was due to higher selling, general and administrative expenses related to increase in revenues for the fourth quarter of 2008.

Operating expenses represented 6.7% of total revenues in the fourth quarter of 2008, slightly down from 6.9% in the fourth quarter of 2007.

The Company recorded $0.36 million in research and development expenses in the fourth quarter of 2008, compared to $0.21 million in the fourth quarter of 2007. The increase in R&D expense was due to the pre-clinical study of Yutian Capsule, a traditional Chinese medicine developed for use in the treatment of lung cancer.

Operating income was $4.2 million in the fourth quarter of 2008, up 24.5% from $3.4 million in fourth quarter of 2007. Operating margin was 17%, as compared to 21% a year ago.

Net income for the fourth quarter of 2008 was $3.5 million, or $0.23 per diluted share, compared to $2.8 million, or $0.17 per diluted share in the fourth quarter of 2007.

Full Year 2008 Results

For the full year 2008, total revenues were $53.6 million, up 27.4% from $42.1 million in 2007. Approximately 97.5% of revenue came from product sales and 2.5% came from medical formula sales. Gross profit for the full year 2008 was $15.6 million, an increase of 25.6% from $12.4 million in 2007. Gross profit margin was 29% in 2008, the same as in 2007. Operating income was $10.9 million, up 29.9% from $8.4 million in 2007. Operating margin was 20%, the same as in 2007. Net income for 2008 was $9.1 million or $0.60 per diluted share, compared to $6.9 million or $0.50 per diluted share in 2007.

Financial Condition

As of December 31, 2008, China Medicine had $2.8 million in cash and cash equivalents, and approximately $32.58 million in working capital, an increase of 14.1% from $28.5 million in 2007. For the year ended December 31, 2008, China Medicine's cash flow from operations was $4.2 million. Stockholders' equity as of December 31, 2008 was $42.8 million, an increase of 38.5% over the $30.9 million recorded as of December 31, 2007.

During the fourth quarter, the Company spent $2.7 million on purchasing and installing equipment for the production of rADTZ. The Company also spent $2.9 million as the deposit on the purchase of the ownership of BCG (Bacillus Calmette-Guerin) vaccine for the prevention of infection in bladder cancer patients post surgery and $2.3 million on exclusive distribution rights for multivitamin food supplement products.

2009 Outlook

"Looking forward to 2009, we expect to see continued growth from our pharmaceutical products distribution business as the Chinese government rolls out its plan to spend RMB850 billion ($123 billion) in the next three years to establish a universal health care system. As a pharmaceutical developer and a leading pharmaceutical distributor in China today, we are committed to further expanding our distribution network, increasing the number of higher margin products in our distribution catalogue, and focusing our R&D efforts on increasing our pipeline of proprietary pharmaceutical products," said Mr. Yang.

"During the first quarter of 2009, we are continuing to make progress in our efforts to introduce to the market recombinant Aflatoxin Detoxifizyme (rADTZ), our novel and innovative product that has the potential to detoxify aflatoxin (AFT), a cancer causing agent, in food and feed. We recently achieved another milestone with rADTZ, where we have successfully completed all rounds of initial rADTZ experiments and testing. The product is currently being reviewed by the Department of Agriculture, China. In addition, we have also applied for a production permit for rADTZ and expect to receive approval in the second quarter of 2009,'' said Mr. Yang.

''The pharmaceutical industry in China is undergoing reform and competitors might see delays in getting new pharmaceutical products approved or receiving Good Manufacturing Practices (GMP) certification for their manufacturing facilities as a result of stricter rules and tighter regulations. However, due to the success of our distribution model, we believe China Medicine is well positioned to take advantage of the increasing demand for good quality healthcare products from the burgeoning middle class and the elderly population in China," concluded Mr. Yang.

Conference Call

China Medicine will hold its fourth quarter conference call for all interested persons at 9:00 a.m. Eastern Time on March 26, 2009 to discuss its results. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: +1-888-419-5570. International callers should dial +1-617-896-9871. When prompted by the operator, mention conference passcode 305-148-03. If you are unable to participate in the call at its scheduled time, a replay will be available for seven days starting on Thursday, March 26 at 11:00 a.m. Eastern Time. To access the replay, dial +1-888-286-8010 (international callers dial +1-617-801-6888), and enter the passcode 278-945-21.

About China Medicine Corporation

China Medicine Corporation is a leading pharmaceutical company that discovers and develops medical formulations and distributes over 2,400 pharmaceutical products in China, including prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements. The Company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to 1,788 drug stores in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at .

Cautionary Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.

                          -FINANCIAL TABLES FOLLOW-


                              Three Months ended       Twelve Months Ended
                                 December, 31              December, 31
                                2008        2007         2008         2007
                                  (unaudited)               (audited)
      Product sales         $24,425,182  14,694,861  $52,307,211  $39,247,130
      Medical formula sales       7,254   1,464,625    1,340,595    2,858,257
        Total revenues       24,432,436  16,159,486   53,647,806   42,105,387

    COST OF GOOD SOLD        18,589,095  11,678,186   38,074,919   29,708,088

    GROSS PROFIT              5,843,341   4,481,300   15,572,887   12,397,299

      Research and
       development              355,868     214,541      840,437      651,990
      Selling, general and
       administrative         1,289,076     895,619    3,804,585    3,330,907
        Total operating
         expenses             1,644,944   1,110,160    4,645,022    3,982,897

    INCOME FROM OPERATIONS    4,198,397   3,371,140   10,927,865    8,414,402

    OTHER INCOME, NET            40,167      11,819       85,622       15,423

     INTEREST                 4,238,564   3,382,959   11,013,487    8,429,825

     TAXES                      753,304     630,371    2,006,137    1,649,114

     INTEREST                 3,485,260   2,752,588    9,007,350    6,780,711

    MINORITY INTEREST            33,179      26,012      118,266       94,658

    NET INCOME                3,518,439   2,778,600    9,125,616    6,875,369

      Foreign currency
       adjustment               135,806     721,233    2,305,499    1,621,672

    COMPREHENSIVE INCOME     $3,654,245   3,499,833  $11,431,115   $8,497,041

      Basic                       $0.23       $0.19        $0.60        $0.56
      Diluted                     $0.23       $0.17        $0.60        $0.50

      Basic                  15,226,742  14,668,310   15,173,113   12,346,208
      Diluted                15,226,742  15,980,110   15,308,529   13,658,007


                           CONSOLIDATED BALANCE SHEETS
                         AS OF DECEMBER 31, 2008 AND 2007

                                                    2008              2007
      Cash                                       $2,791,814        $5,767,774
      Notes receivable                              600,911                --
      Accounts receivable, trade, net of
       allowance for doubtful accounts of
       $96,609 and $55,640 as of December
       31, 2008 and 2007, respectively           19,225,091        13,626,347
      Inventories                                 4,725,322         3,948,460
      Advances to suppliers                       6,121,974         5,983,277
      Other current assets                          192,080            81,221
        Total current assets                     33,657,192        29,407,079

    EQUIPMENT, net                                3,761,637         1,388,919

      Long term prepayment                        6,014,920           678,237
      Intangible assets, net                      1,247,567         1,166,003
        Total other assets                        7,262,487         1,844,240

          Total assets                          $44,681,316       $32,640,238


      Accounts payable, trade                       $61,243           $76,907
      Other payables and accrued liabilities         50,559            70,343
      Customer deposits                             151,429           203,281
      Taxes payable                                 772,289           468,184
      Liquidated damages payable                     44,003            44,003
        Total liabilities                         1,079,523           862,718

    MINORITY INTEREST                               835,532           893,337

      Preferred stock, $0.0001 par value;
       10,000,000 shares authorized, 0 and
       111,649 shares issued and outstanding
       at December 31, 2008 and 2007,
       respectively                                      --                11
      Common stock, $0.0001 par value;
       100,000,000 shares authorized,
       15,226,742 and 14,821,641 shares
       issued and outstanding at December
       31, 2008 and 2007, respectively                1,522             1,482
      Paid-in capital                            13,011,012        12,560,078
      Statutory reserves                          3,178,861         2,191,230
      Retained earnings                          22,146,572        14,008,587
      Accumulated other comprehensive income      4,428,294         2,122,795
        Total shareholders' equity               42,766,261        30,884,183

          Total liabilities and
           shareholders' equity                 $44,681,316       $32,640,238


                  FOR THE YEARS ENDED DECEMBER 31, 2008 AND 2007

                                                   2008               2007
     Net income                                 $9,125,616         $6,875,369
     Adjustments to reconcile net income
      to cash used in operating activities:
       Minority interest                          (118,266)           (94,658)
       Depreciation and amortization               420,769            303,957
       Bad debt expenses                            36,428             18,495
       Loss on sale of assets                        9,416                 --
        stock based compensation                    88,463            333,870
       Amortization of deferred expenses                --            325,687
      Change in operating assets and
       Notes receivable                           (590,466)                --
       Accounts receivable, trade               (4,786,654)        (5,879,829)
       Inventories                                (491,874)        (1,840,170)
       Advances to suppliers                       461,695         (2,535,589)
       Other current assets                       (105,081)           (34,728)
       Accounts payable, trade                     (20,683)          (120,129)
       Other payables - related parties                 --            (30,000)
       Other payables and accrued
        liabilities                                (24,555)            45,119
       Customer deposits                           (64,938)           176,763
       Taxes payable                               266,606            145,730
       Accrued Expenses                              2,608                 --
        Net cash provided by (used in)
         operating activities                    4,209,084         (2,310,113)

       Purchase of equipment                    (2,666,014)          (389,588)
       Long term prepayment                     (5,197,253)                --
        Net cash used in investing
         activities                             (7,863,267)          (389,588)

     Proceeds from exercise of warrants
      and options                                  362,500          7,829,681
        Net cash provided by financing
         activities                                362,500          7,829,681

    EFFECT OF EXCHANGE RATE ON CASH                315,723            266,314

    (DECREASE) INCREASE IN CASH                 (2,975,960)         5,396,294

    CASH, beginning of year                      5,767,774            371,480

    CASH, end of year                           $2,791,814         $5,767,774

    For more information, please contact:

    Company Contact:
     Ms. Huizhen Yu
     Chief Financial Officer
     China Medicine Corp
     Tel:   +86-20-8739-1718

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:   +1-646-213-1915 (NY Office)

SOURCE China Medicine Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. China Medical Technologies Announces Receipt of SFDA Quality Testing Certificate for its SPR-based Analysis System
2. China Information Security Technology, Inc. Announces that Its Medical Case Statistics Software Selected for Exclusive Contract
3. China Pharma Holdings, Inc. Reports Record 2008 Year End Financial Results and Corporate Updates
4. China Medicine Announces Conference Call to Discuss Fourth and Fiscal Year 2008 Results
5. China Yongxin Pharmaceuticals Inc. Launches Electronic Diagnosis System in its Changchun Drugstores
6. China Nepstar Chain Drugstore Announces Dividend
7. China Sky One Medical to Attend Two Conferences in March
8. China Sky One Medical, Inc. Obtains SFDA Approval for Policresulen Vaginal Suppositories
9. China Pharma Holdings, Inc. to Host Fourth Quarter 2008 Earnings Conference Call at 8:30 a.m. EDT Wednesday March 18, 2009
10. China Yingxia International, Inc.s chairwoman and CEO is in talks with investors in China
11. China Healthcare Acquisition Corp. Announces Stockholder Approval of Charter Amendment to Permit Early Distribution of Its Trust Fund and to Permit Its Continued Existence Without Blank Check Company Provisions and Sets Payment Date
Post Your Comments:
(Date:10/13/2017)... ... 13, 2017 , ... ProVest Insurance Group, a family managed ... Raleigh regions, is organizing an extended charity drive to benefit the family of ... , After struggling since birth with several health challenges, T.J. was later diagnosed ...
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of ... ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership in ... It also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis ... global supply chains, has published the first annual edition of its Global ... more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that ... ... Risk & Performance Index ...
Breaking Medicine Technology: